ABBN.SW: $86.60 ▲ 0.50 (0.58%)ASML.AS: $1,583.20 ▲ 22.40 (1.44%)ENR.DE: $160.94 ▼ -1.56 (-0.96%)GLEN.L: $534.60 ▼ -0.70 (-0.13%)IFX.DE: $81.80 ▲ 1.24 (1.53%)NOKIA.HE: $12.40 ▲ 0.40 (3.33%)RIO.L: $7,262.00 ▼ -2.00 (-0.03%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Clearside Biomedical, Inc.

CLSD - NASDAQ

Identifiants & Marche

Ticker CLSD
ISIN US1850631045
CIK 0001539029
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.